David Kirn
CEO
4D Molecular Therapeutics
4D Molecular Therapeutics develops customized gene therapies using a proprietary vector platform optimized through directed evolution, targeting diseases in ophthalmology, pulmonology, and cardiology. Their products aim to provide curative treatments for conditions with significant unmet medical needs, such as reducing the treatment burden for wet age-related macular degeneration.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$300MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many genetic diseases lack effective treatments, and traditional gene therapies often struggle with targeted delivery and efficient gene expression in the affected tissues. This limits their potential to provide long-lasting therapeutic benefits or cures.
Solution
4D Molecular Therapeutics (4DMT) develops genetic medicines utilizing a proprietary, evolved vector platform for targeted gene delivery. Their approach involves directed evolution to create customized vectors optimized for specific tissues and diseases, enhancing therapeutic efficacy. The company's pipeline focuses on ophthalmology, pulmonology, and cardiology, aiming to address diseases with significant unmet medical needs by delivering genes directly to affected cells, promoting sustained therapeutic effects and potentially curative outcomes.
Target Audience
The primary target audience includes patients suffering from genetic diseases in ophthalmology, pulmonology, and cardiology, as well as physicians and healthcare providers seeking advanced therapeutic options.
Features
- Proprietary vector platform optimized through directed evolution for tissue-specific targeting
- Customized vector design for enhanced gene expression and therapeutic efficacy
- Focus on genetic medicines for ophthalmology, pulmonology, and cardiology
- Development of therapies with the potential to improve patient lives or cure diseases
- Programs targeting wet age-related macular degeneration (AMD) and cystic fibrosis (CF)
- Inhalable gene therapy for cystic fibrosis showing early positive signs in clinical trials